P. C. Thuss-Patience
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (NCT03966118) | P. C. Thuss-Patience | 2019-04-01 |
Track P. C. Thuss-Patience automatically
Every clearance here is in the API, with alerts when new ones post.